Blog

  • Morbidity in Males With 45,X/46,XY Resembles the Morbidity Pattern in Turner Syndrome

    Morbidity in Males With 45,X/46,XY Resembles the Morbidity Pattern in Turner Syndrome

    Agnethe Berglund, Claus Højbjerg Gravholt, Kirstine Stochholm
    The Journal of Clinical Endocrinology & Metabolism, Volume 110, Issue 9, September 2025, Pages 2556–2564
    https://doi.org/10.1210/clinem/dgae912

    Abstract

    Context

    Few studies have reported on males with 45,X/46,XY mosaicism. Most studies stem from pediatric settings, and knowledge of natural history and long-term health outcomes are therefore lacking.

    Objective

    To describe long-term health outcomes in males with 45,X/46,XY in comparison to the general population.

    Design

    A national population-based registry study.

    Setting

    A public uniform healthcare system.

    Patients and Controls

    All males in Denmark diagnosed with 45,X/46,XY mosaicism from 1960–2016 (n = 135) and 1:100 age-matched males from the background population.

    Main Outcome Measures

    Hospital diagnoses, prescribed medication, and surgery codes were analyzed using a Cox proportional hazards regression model yielding hazard ratios (HRs).

    Results

    45,X/46,XY was associated with an increased overall risk of being referred to the hospital [HR = 1.6, confidence interval (CI): 1.3–1.9], undergoing surgery (HR = 1.8, CI: 1.4–2.2), and being prescribed medication (HR = 1.2, CI: 1.03–1.5). This risk applied to 15/18 diagnostic groups, 6/14 medication groups, and 10/16 surgery groups. Diagnoses with increased HRs included diabetes, thyroid disorders, obesity, hypertension, ischemic heart disease, osteoporosis, and inflammatory bowel disease. Half of all 45,X/46,XY males (69/135) had ≥1 diagnosis related to the genitourinary system, and nearly one-third (39/135) underwent urogenital surgery.

    Conclusion

    45,X/46,XY mosaicism in males impacts long-term health significantly. The morbidity pattern includes a wide range of diseases, most known to occur at increased frequencies in Turner syndrome. The study underscores the importance of identifying these males and following them with systematic screening as in Turner syndrome.

     

    Continue Reading

  • Neuroendocrinology and the Genetics of Obesity

    Neuroendocrinology and the Genetics of Obesity

    Rebecca E Ruggiero-Ruff and Djurdjica Coss
    Endocrinology, Volume 166, Issue 9, September 2025, bqaf121
    https://doi.org/10.1210/endocr/bqaf121

    Abstract

    The increase in the incidence of obesity has coincided with changes in lifestyle, diet, and environment. Comorbidities associated with obesity include cardiovascular disease, diabetes, musculoskeletal disorders, stroke, and thromboembolism, affecting public health. The effect of increased weight has recently become even more obvious, since obesity has been significantly associated with increased severity and higher mortality among COVID-19 patients. The need to decrease rates of obesity prompted a surge in the use of glucagon-like peptide-1 agonist medications. Twin studies, however, determined that increased weight has a large genetic component, estimating the heritability of obesity to be 45% to 70%. Surprisingly, obesity due to known single gene mutation comprises only 5% to 10% of individuals, who mostly exhibit early-onset severe obesity. Genome-wide linkage studies and association studies identified more than 250 genes associated with obesity, but each of these has a relatively small effect size. Further, several genetic syndromes, associated with neurodevelopmental disabilities and congenital malformations, encompass obesity in their constellation of symptoms. This review will summarize several known genetic causes of obesity, focusing specifically on how they relate to the brain circuitry that regulates food intake and energy homeostasis. The review will indicate a need for further studies to integrate the role of diet and environmental contribution with genetic components of this multifactorial condition. Given that genetics of obesity is unlikely to explain the recent dramatic temporal increase in the prevalence of obesity, our review will point to the need to understand interactions between genes and other contributing environmental or sex-dependent factors.

     

    Continue Reading

  • Pakistan PM Shehbaz Sharif Confirms US Visit For UNGA; Sharif-Trump Meeting Likely | Asia

    Pakistan PM Shehbaz Sharif Confirms US Visit For UNGA; Sharif-Trump Meeting Likely | Asia

    Pakistan PM Shehbaz Sharif to address UNGA on September 26; possible meeting with Donald Trump on sidelines, with Army Chief Asim Munir also present.

    Photo : AP

    Islamabad, September 16: Pakistan Prime Minister Shehbaz Sharif has confirmed his upcoming visit to the United States to attend the United Nations General Assembly (UNGA), where he is scheduled to deliver his address on September 26. Pakistan is desperate to ease mounting pressure at home and abroad, and hopes to secure relief on both the economic and diplomatic fronts — but the stakes couldn’t be higher.

    Sharif-Trump Meeting Likely On Sidelines

    According to diplomatic sources, a meeting between Shehbaz Sharif and Donald Trump is likely on the sidelines of the UNGA. To accommodate the possibility, Pakistan has strategically reserved three to four time slots for the bilateral engagement.

    Army Chief Asim Munir To Join Delegation

    Sources also confirmed that Pakistan’s Chief of Army Staff, Field Marshal Asim Munir, will be part of the high-level delegation traveling with the Prime Minister. His presence underscores the significance of the visit, especially given the evolving regional security dynamics.

    India-Pakistan Conflict & US Ties On Agenda

    The discussions are expected to cover a wide range of issues. The recent India-Pakistan conflict is likely to feature prominently, alongside matters related to US-Pakistan trade, investment opportunities, and strategic cooperation.

    High Stakes For Pakistan’s Diplomacy

    Sharif’s UNGA address and possible meeting with Trump come at a crucial time for Islamabad as it seeks to balance regional tensions with its push for economic stability and stronger ties with Washington.


    Continue Reading

  • iOS 26 update impacting your iPhone battery life? Apple says it is normal

    iOS 26 update impacting your iPhone battery life? Apple says it is normal

    iOS 26 is one of the biggest updates in iPhone history. The new version brings the highly anticipated liquid glass theme to all supported iPhones. iPadOS 26 brings the same design to iPads. Before you update your iPhone (or iPad), here’s what Apple wants you to know about any potential impact on battery life.

    On September 15, the day of iOS 26 release, Apple updated its page titled, ‘About Apple software updates.’ The company gave a brief on why software updates are important for all devices and the new updates that they bring.

    There is one section of the page that talks about performance and battery life. Apple informed users that while upgrading their iPhone or any other Apple device to the latest version of a major release (like iOS 26), there might be a noticeable decrease in battery life.

    However, this was not meant to be a permanent issue. Apple stated, “This is normal, as your device needs time to complete the setup process in the background.”

    Users who are updating their iPhone to iOS 26 should not be too worried if they see a drop in battery life at first. After the background work is completed, the device is expected to bring back the same level of endurance while providing a seamless software experience.

    The iPhone 17 series and iPhone Air will ship with iOS 26 out of the box when sales begin on Friday, September 19.

    Which iPhones are compatible with iOS 26?

    Apple is the pioneer when it comes to OS updates on smartphones. Every iPhone receives multiple years of support. This is also the case for iOS 26. You can experience the new liquid glass theme even on an old iPhone. Here’s the full list for quick reference:

    • iPhone Air
    • iPhone 17 Pro Max
    • iPhone 17 Pro
    • iPhone 17
    • iPhone 16e
    • iPhone 16 Pro Max
    • iPhone 16 Pro
    • iPhone 16 Plus
    • iPhone 16
    • iPhone 15 Pro Max
    • iPhone 15 Pro
    • iPhone 15 Plus
    • iPhone 15
    • iPhone 14 Pro Max
    • iPhone 14 Pro
    • iPhone 14 Plus
    • iPhone 14
    • iPhone 13 Pro Max
    • iPhone 13 Pro
    • iPhone 13
    • iPhone 13 mini
    • iPhone 12 Pro Max
    • iPhone 12 Pro
    • iPhone 12
    • iPhone 12 mini
    • iPhone 11 Pro Max
    • iPhone 11 Pro
    • iPhone 11
    • iPhone SE (3rd generation)
    • iPhone SE (2nd generation)

    The iPhone 11 series is the oldest lineup in the list of compatible devices, having launched in 2019. It is likely that iOS 26 is the last major release for iPhone 11, 11 Pro and 11 Pro Max.

    – Ends

    Published By:

    Armaan Agarwal

    Published On:

    Sep 16, 2025

    Continue Reading

  • Researchers Capture New Antibiotic Resistance Mechanisms

    Researchers Capture New Antibiotic Resistance Mechanisms

    Scientists from the University of Illinois Urbana-Champaign have developed a method to isolate genes from amounts of microbial DNA so tiny that it would take 20,000 samples to weigh as much as a single grain of sugar. In a new paper, the researchers used the method to discover previously unknown antibiotic resistance genes in bacterial DNA isolated from human stool and from fish tanks at Chicago’s Shedd Aquarium.

    “With antibiotic resistance on the rise, it’s more important than ever to understand the full diversity of mechanisms bacteria may be using to inactivate or avoid antibiotics,” said Terence Crofts (IGOH), assistant professor in the Department of Animal Sciences, part of the College of Agricultural, Consumer and Environmental Sciences at Illinois. “If we can get a clearer view of the antibiotic resistance genes that exist out in the environment, that will give biomedical researchers a chance to look out for them in the clinic and potentially design more effective drugs.”

    Crofts developed the method, known as METa assembly, to improve a microbiology tool known as a functional metagenomic library, which enables researchers to capture bacterial genes from the environment. The method allows researchers to collect soil, stool, or other environmental samples and screen for the presence of potentially new microbial genes without having to culture the microbes or sequence their genomes. But METa assembly requires 100 times less DNA than standard functional metagenomic libraries, which is useful where microbes are scarce or when researchers can’t take large samples.

    “We used to take the DNA out of the bacteria and just sequence it, but there are so many new genes in those environments that our sequencing ability has far outstripped our ability to actually guess at the functions of those genes,” Crofts said. “A lot of these genes have unknown functions, so functional metagenomic screens are a way to get around that problem.”

    Instead of sequencing the DNA, the researchers use an enzyme to chop it into gene-size pieces, which they then introduce to E. coli bacteria in the lab. E. coli, which is easier to grow in lab settings than many other microbes, incorporates the foreign DNA into its genetic machinery and begins to take on its traits. Crofts says antibiotic resistance traits are especially well-suited for study using functional metagenomic libraries because they’re usually controlled by a single gene, and it’s easy to tell whether bacteria have it or not.  

    “If E. coli has a resistance gene, it can survive an antibiotic. If it doesn’t, it dies,” he said. “We might have 10 million E. coli cells in a petri dish with 10 million unique random chunks of environmental DNA. If we expose it to a particular antibiotic and only 10 colonies survive, we know those 10 had a resistance gene. Then it becomes very easy to take those colonies and sequence the chunk of DNA they grabbed from that environmental sample.”

    Even if the sequencing result turns up genes for unknown proteins, the researchers know that they have a role in antibiotic resistance and can immediately drill down to study their mechanisms.

    Crofts and his team tested the method on a sample of water from a large tank at Chicago’s Shedd Aquarium, where microbes are far less populous than in other environments like soil. They also tested a tiny sample from a product that usually teems with bacteria: human fecal matter.

    “Because aquatic samples are usually less dense with microbes, you usually can’t get as much DNA out of them, but we showed that we could still make good libraries from the aquarium sample,” Crofts said. “It’s also significant that we could make a functional metagenomic library from just a swab sample of fecal matter. That could be useful for clinical settings.”

    The team didn’t just make libraries from these samples, they made new discoveries about how microbes resist antibiotics. For example, in tetracycline-resistant sequences from Shedd Aquarium, the researchers identified new types of efflux pumps — protein channels that pump substances across the cell membrane — that remove tetracycline from cells.

    Interestingly, some of the E. coli colonies from the human fecal sample resisted a group of antibiotics known as streptothricins. These were tested in the 1940s, but were never brought to market due to kidney toxicity in mammals. But with so much resistance in the current antibiotic landscape, Crofts says biomedical researchers are looking into streptothricin again (in less toxic forms).

    “We found what looks like an entirely new family of streptothricin resistance proteins in our sequences,” he said. “Streptothricin is being brought up as this potentially clinically useful antibiotic, but we should really be trying to find out what resistance is already out there in the environment. And instead of making traditional streptothricins less toxic, maybe we should make a next-generation analog that can beat the antibiotic resistance mechanisms that may already exist in nature.”  

    Crofts plans to deploy his METa assembly method to agricultural systems — sampling soil and from “nose to tail” in livestock — since antibiotic resistance not only occurs on the farm, it often originates on the farm.

    “We produce a lot of antibiotics by culturing soil bacteria that make antibiotics as weapons to fight other bacteria. So, soils therefore have a very rich diversity of antibiotic resistance genes,” Crofts said. “Agriculture puts all these mammals in close association with this reservoir of antibiotic resistance genes in the soil. Since we’re giving these animals large amounts of antibiotics it becomes a very ripe environment for resistance to develop and jump into bacteria that can impact our own health.”

    Reference: Allman HM, Bernate EP, Franck E, Oliaro FJ, Hartmann EM, Crofts TS. Preparation of functional metagenomic libraries from low biomass samples using METa assembly and their application to capture antibiotic resistance genes. mSystems. 2025:e01039-25. doi: 10.1128/msystems.01039-25

    Continue Reading

  • New Species of “Living Fossil” Fish Found Hiding in Plain Sight After 150 Years

    New Species of “Living Fossil” Fish Found Hiding in Plain Sight After 150 Years

    Reconstruction of a large mawsoniid coelacanth from the British Rhaetian. Credit: Daniel Phillips

    Researchers found dozens of Triassic coelacanth fossils in UK museums. The fish were once mistaken for reptile bones.

    The coelacanth is often called a “living fossil.” Once believed to have vanished millions of years ago, it was unexpectedly rediscovered in 1938 when one was caught in the Indian Ocean.

    Since then, several more specimens have been documented, yet their fossil record has remained incomplete. In a recent study, Jacob Quinn and his collaborators from the University of Bristol and the University of Uruguay uncovered coelacanth fossils in museum collections that had gone unnoticed for over 150 years.

    Fossils from the Triassic seas

    The newly identified specimens date to the closing stages of the Triassic Period, around 200 million years ago, when the region that is now the UK was positioned in more tropical latitudes.

    “During his Master’s in Palaeobiology at Bristol, Jacob realised that many fossils previously assigned to the small marine reptile Pachystropheus actually came from coelacanth fishes,” said Professor Mike Benton, one of Jacob’s supervisors. “Many of the Pachystropheus and coelacanth fossils have uncanny similarities, but importantly, Jacob then went off to look at collections around the country, and he found the same mistake had been made many times.”

    Comparison Between the Clavicles of the British Triassic and Mawsonia Gigas
    Comparison between clavicles (collar bones) from (A) the British Triassic and (B) the largest known coelacanth, Mawsonia gigas, from the Cretaceous of Brazil. Credit: University of Bristol

    “It is remarkable that some of these specimens had been sat in museum storage facilities, and even on public display, since the late 1800s, and have seemingly been disregarded or identified as bones of lizards, mammals, and everything in-between,” said Jacob. He continued “from just four previous reports of coelacanths from the British Triassic, we now have over fifty.”

    Jacob made X-ray scans of many specimens to confirm the identifications. The specimens mostly belong to an extinct group of coelacanths, the Mawsoniidae, but are closely related to the living fish.

    Insights into ancient ecosystems

    Co-author Pablo Toriño, a world expert on coelacanths, located in Uruguay, added, “Although the material we identify occurs as isolated specimens, we can see that they come from individuals of varying ages, sizes, and species, some of them up to one metre long, and suggesting a complex community at the time.”

    “The coelacanth fossils all come from the area of Bristol and Mendip Hills, which in the Triassic was an archipelago of small islands in a shallow tropical sea,” said co-supervisor Dr David Whiteside. “Like modern-day coelacanths, these large fishes were likely opportunistic predators, lurking around the seafloor and eating anything they encountered, probably including these small Pachystropheus marine reptiles, which is ironic given their fossils have been confused with those of coelacanths for decades.”

    Reference: “Coelacanthiform fishes of the British Rhaetian” by Jacob G. Quinn, David I. Whiteside, Pablo Toriño, Evangelos R. Matheau-Raven and Michael J. Benton, 7 September 2025, Journal of Vertebrate Paleontology.
    DOI:10.1080/02724634.2025.2520921

    Never miss a breakthrough: Join the SciTechDaily newsletter.

    Continue Reading

  • Bayern Munich backed to be too strong for Chelsea in Champions League opener as Germany legend says Harry Kane & Co among seven true contenders for European title

    Bayern Munich backed to be too strong for Chelsea in Champions League opener as Germany legend says Harry Kane & Co among seven true contenders for European title

    Continue Reading

  • FIA and Formula 1 announce 2026 Sprint Calendar

    FIA and Formula 1 announce 2026 Sprint Calendar

    The FIA and Formula 1 have today revealed the six venues set to host F1 Sprint events during the 2026 FIA Formula One World Championship season – including three exciting new locations.

    The 2026 season will introduce a new era of regulations to the sport and host its sixth year of the Sprint format. The first F1 Sprint of 2026 will take place in Shanghai, followed by Miami, with both Grands Prix hosting a Sprint weekend for the third consecutive year. Silverstone returns to the Sprint Calendar for the first time since the format’s inaugural event in 2021, and Montréal, Zandvoort and Singapore are all set to host their first ever Sprint weekend.

    The F1 Sprint provides competitive action on each day of a race weekend. Sprint Qualifying takes place on Friday following Free Practice 1, with the Sprint race and Grand Prix Qualifying on Saturday, before the weekend culminates with the Grand Prix on Sunday. The format has continued to prove popular among fans across the world, leading to strong fan attendance and viewership figures across broadcast, digital and social platforms.

    In 2024, TV viewership for Sprint weekends was on average 10% greater than non-Sprint weekends, and the sport continues to see an upward trend following the opening three Sprint weekends of the 2025 season. Lewis Hamilton’s maiden Ferrari win in the Shanghai Sprint saw an 84% live TV audience increase across Formula 1’s top 15 markets in comparison to last year’s event, and the Miami Grand Prix Sprint, won by Lando Norris, was watched by 26.6 million TV viewers, an 18% increase versus last year. This year’s Sprint event in Belgium, won by Max Verstappen, saw a significant rise in TV viewership in both heritage and growth markets, including in Germany (+40%), France (+42%), China (+182%), and Argentina (+9%), when compared to the Sprint event in Europe in 2024.

    In addition to the confirmation of the Sprint Calendar, the FIA has published the official start times for all Grands Prix in 2026 which can be found here.

     

    The dates of the F1 Sprint events in 2026 are:

    Date Country Venue
    13-15 March China Shanghai
    01-03 May USA Miami
    22-24 May Canada Montréal
    03-05 July Great Britain Silverstone
    21-23 August Netherlands Zandvoort
    09-11 October Singapore Singapore

    Mohammed Ben Sulayem, President of the FIA, said:

    “The Sprint format has become an increasingly exciting part of the FIA Formula One World Championship, delivering high-intensity racing and added entertainment for fans around the world. As we look ahead to a landmark 2026 season featuring a new generation of cars and regulations, I’m pleased to see the Sprint evolving alongside our broader ambitions for the sport. The inclusion of new venues alongside returning favourites reflects the continued enthusiasm from promoters, teams and fans alike. We will continue to work closely with FOM, the teams, our officials, and the drivers to ensure the Sprint format enhances the championship.”

    Stefano Domenicali, President and CEO of Formula 1, said:

    “The F1 Sprint has continued to grow in positive impact and popularity since it was introduced in 2021. With four competitive sessions rather than two during a conventional Grand Prix weekend, F1 Sprint events offer more action each day for our fans, broadcast partners, and for the promoters – driving increased attendance and viewership. We’re also proud to have welcomed Gatorade as an Official Partner of F1 Sprint, demonstrating the huge interest in the event from an iconic global brand. The 2026 season will usher in a new era of regulations, so having three new Sprint venues will only add to the drama on track. I want to thank the FIA, all the promoters, our partners, marshals, volunteers, and local sporting clubs for continuing to make the Sprint a big success and we all look forward to giving our fans more incredible racing and excitement in the 2026 season.”

    Continue Reading

  • Scientists discover key cause of liver disease, promising step towards new treatment

    Scientists discover key cause of liver disease, promising step towards new treatment



    Scientists discover key cause of liver disease, promising step towards new treatment

    Scientists have revealed in a new study that harmful bacteria could be a previously unknown cause of fatty liver disease.

    It is commonly observed that excessive alcohol intake is the major cause of liver disease, but experts say anything that can increase fat in and on the liver could be driving the escalation in cases of fatal liver cancer.

    Death tolls have been continuously rising with figures having quadrupled in the past 50 years.

    Canadian researchers have made a groundbreaking discovery of a way of controlling blood sugar levels and mitigating liver damage, especially in obese patients.

    The study was published in the journal Cell Metabolism and revealed that scientists were able to identify and isolate a molecule produced by gut bacteria that parks the liver to make sugar and fat.

    Professor Jonathan Schetzer at McMaster University was of the view that this is a completely new way to think about treating metabolic diseases like fatty liver disease.

    Further he explained that we have known for nearly a century that muscles and the liver exchange lactate, and we discovered a new branch of the cycle where gut bacteria were also involved.

    The most common form of liver disease, which affects around 1 in 5 in the UK, is metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease.

    This particular condition is caused by excessive fat that triggers inflammation.

    It can cause liver failure or even cancer if left untreated and it can also cause a higher risk of type 2 diabetes.

    There has been a significant increase in liver disease in the UK, and the prime concern is that symptoms are often unnoticeable until the condition is advanced.

    There has been a strong sense of urgency to tackle the UK’s rising obesity rate to mitigate pressures on the National Health Service.

    The recent data suggests that nearly two-thirds of adults in England are obese, with 260,000 people joining that category last year.

    Weight loss jabs are increasingly becoming popular in the UK, with an estimated 1.5 million people now using them through the NHS or private clinics, while millions are eligible for these treatments.

    Continue Reading

  • Digital Test Boosts Alzheimer’s Detection in Primary Care

    Digital Test Boosts Alzheimer’s Detection in Primary Care

    Researchers at Lund University in Sweden have developed a digital cognitive test for diagnosing Alzheimer’s disease that is intended for use in primary care.

    “This digital test, which patients perform on their own with minimal involvement from healthcare personnel, improves the primary care physician’s ability to determine who should be further examined by blood tests for Alzheimer’s pathology early in the investigation phase,” says Professor Oskar Hansson, who led the study alongside Pontus Tideman.

    The study in brief:

    • Clinical memory research // quantitative study, applied research // cross-sectional study // 2 groups with 223 and 403 patients, respectively
    • The researchers have designed a digital cognitive test, BioCog, intended for use in primary care as a first step in the investigation process for Alzheimer’s disease.
    • The test is self-administrated and tests the patient’s cognitive abilities, primarily memory but also attention, and can show whether cognition is impaired. Patients whose tests show impaired cognition continue the assessment process with additional blood tests to determine whether Alzheimer’s pathology is the cause of the impairment.

    Alzheimer’s disease is the most common cause of dementia. As new disease-modifying treatments for Alzheimer’s disease are now becoming available, both early and accurate diagnosis in a resource-efficient assessment process are becoming increasingly important, as not everyone responds to the new drugs. Seeking medical care for cognitive impairment is not necessarily the result of Alzheimer’s disease – it can for example be caused by depression, fatigue or other dementias.

    “Primary care does not have the resources, time or specialist knowledge to investigate possible Alzheimer’s disease in the same way as specialised memory clinics. And this is where a digital cognitive test can make the biggest difference,” says Oskar Hansson, professor of neurology at Lund University.

    Unlike pen-and-paper tests, which are generally used to assess cognitive impairment, digital tests provide a more detailed picture. More aspects and new variables that could not previously be measured as easily are included.

    “The vast majority of people who experience memory loss will first seek treatment at their health centre. Our new digital test provides a first objective picture – at an earlier stage and with greater precision – of which patients have cognitive impairment indicative of Alzheimer’s disease. This indicates who should proceed with the blood test that measures the level of phosphorylated tau and is able to detect Alzheimer’s pathology in the brain with high accuracy,” says Pontus Tideman, doctoral student in the research group, Clinical Memory Research at Lund University and psychologist at the Memory Clinic, Skåne University Hospital.

    At the moment, these blood tests are only available in specialised clinics/memory clinics in hospitals. In the long term, they will also be available in primary care, but doing blood tests on all patients presenting with cognitive problems is not the intention.

    The researchers believe that the digital tool could be of great benefit, as it is currently very challenging to diagnose Alzheimer’s disease during a 15 to 20-minute patient encounter. This is where digital tools, which measure cognitive skills in an objective way, can make a big difference:

    “The unique aspect of our BioCog test is that unlike other digital tests, it has been evaluated in a primary care population, i.e. patients seeking treatment at a health centre because they are experiencing cognitive problems, such as memory problems. Combining the results of the digital test and the blood test increases the accuracy of diagnosing Alzheimer’s disease. The purpose of the test is to make things easier for primary care doctors,” says Linda Karlsson, MSc in engineering physics and doctoral student in the research group, Clinical Memory Research at Lund University.

    About the test

    The digital test is done by the patient individually on a tablet computer. The test measures:

    • memory (memorising ten words)
    • cognitive processing speed and attention (how quickly or slowly they process information)
    • orientation (what year, day etc.)
    • delayed recall (recalling previously memorised information)
    • recognition (among 30 words, recognise the ten words previously memorised)

    The test measures aspects and variables that could not easily be measured in the past using pen-and-paper tests, such as how long it takes the patient to search among the words or how quickly they tap the screen. The combination of the sub-tests produces a result that is highly likely to indicate whether or not the patient has a cognitive impairment and can help the physician to decide which patients to take a blood test from, and ultimately which patients may benefit from the new drug treatments for Alzheimer’s disease.

    Reference: Tideman P, Karlsson L, Strandberg O, et al. Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers. Nat Med. 2025. doi: 10.1038/s41591-025-03965-4

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    Continue Reading